Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
Authors
Keywords
-
Journal
SLAS Discovery
Volume -, Issue -, Pages 247255522091295
Publisher
SAGE Publications
Online
2020-03-20
DOI
10.1177/2472555220912955
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
- (2019) Suzanne Trudel et al. Blood Cancer Journal
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo
- (2019) Brian H. White et al. JOURNAL OF MEDICINAL CHEMISTRY
- A phase 1, randomized, single ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S, an anti-Staphylococcus aureus THIOMAB™ antibody-antibiotic conjugate, in healthy volunteers
- (2019) Melicent Peck et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Recent Chemical Approaches for Site‐specific Conjugation of Native Antibodies: Technologies toward Next Generation Antibody‐Drug Conjugates
- (2019) Kei Yamada et al. CHEMBIOCHEM
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- Hybridoma technology: the preferred method for monoclonal antibody generation for in vivo applications
- (2019) Samantha Zaroff et al. BIOTECHNIQUES
- Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
- (2019) Edith A. Perez et al. BMC CANCER
- Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity
- (2019) Yijun Shen et al. mAbs
- Modulating Antibody–Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification
- (2018) Dian Su et al. BIOCONJUGATE CHEMISTRY
- Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells
- (2018) Philip E. Brandish et al. BIOCONJUGATE CHEMISTRY
- ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies
- (2018) Francesca Zammarchi et al. BLOOD
- Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
- (2018) Glenwood D. Goss et al. CANCER
- LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
- (2018) James W. Purcell et al. CANCER RESEARCH
- Phase 1 Trials of anti-ENPP3 antibody drug conjugates in advanced refractory renal cell carcinomas
- (2018) John A Thompson et al. CLINICAL CANCER RESEARCH
- FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
- (2018) Emily Y. Jen et al. CLINICAL CANCER RESEARCH
- Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
- (2018) Anastasios Stathis et al. INVESTIGATIONAL NEW DRUGS
- Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
- (2018) Vaheh Oganesyan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
- (2018) Yelena Kovtun et al. MOLECULAR CANCER THERAPEUTICS
- A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)
- (2018) Michael L. Miller et al. MOLECULAR CANCER THERAPEUTICS
- Glucuronide-linked antibody-tubulysin conjugates display activity in MDR+ and heterogeneous tumor models
- (2018) Patrick J. Burke et al. MOLECULAR CANCER THERAPEUTICS
- A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
- (2018) Tomomi Nakayama Iwata et al. MOLECULAR CANCER THERAPEUTICS
- Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of Its Identified Metabolite
- (2018) Josh T. Snyder et al. MOLECULAR PHARMACEUTICS
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia
- (2018) Kelly J. Norsworthy et al. ONCOLOGIST
- Adnectin–drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors
- (2018) Daša Lipovšek et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-drug Conjugate Targeting PSMA, in Pre-clinical Models of Prostate Cancer
- (2018) Song Cho et al. MOLECULAR CANCER THERAPEUTICS
- MORAb-202, an antibody drug conjugate utilizing humanized anti-human FRa farletuzumab and the microtubule-targeting agent eribulin, has potent anti-tumor activity
- (2018) Xin Cheng et al. MOLECULAR CANCER THERAPEUTICS
- First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
- (2018) John H. Strickler et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
- (2018) Kimio Yonesaka et al. ONCOGENE
- Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
- (2018) Cristina L. Abrahams et al. Oncotarget
- DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance
- (2017) Naoki Takegawa et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates
- (2017) Marion Bouillon-Pichault et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
- (2017) Charles M Rudin et al. LANCET ONCOLOGY
- Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
- (2017) Julian Andreev et al. MOLECULAR CANCER THERAPEUTICS
- Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)
- (2017) Robert M. Sharkey et al. MOLECULAR CANCER THERAPEUTICS
- Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates
- (2017) Fu Li et al. MOLECULAR CANCER THERAPEUTICS
- Efficient Preparation of Site-Specific Antibody–Drug Conjugates Using Cysteine Insertion
- (2017) Nazzareno Dimasi et al. MOLECULAR PHARMACEUTICS
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
- (2017) Marc Damelin et al. Science Translational Medicine
- Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
- (2017) Yoriko Yamashita-Kashima et al. Oncology Letters
- IgG Fc engineering to modulate antibody effector functions
- (2017) Xinhua Wang et al. Protein & Cell
- New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
- (2017) Isabel Corraliza-Gorjón et al. Frontiers in Immunology
- Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
- (2017) Ricarda M. Hoffmann et al. OncoImmunology
- Advances in recombinant antibody manufacturing
- (2016) Renate Kunert et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
- (2016) Hans-Peter Gerber et al. BIOCHEMICAL PHARMACOLOGY
- Natural Product Splicing Inhibitors: A New Class of Antibody–Drug Conjugate (ADC) Payloads
- (2016) Sujiet Puthenveetil et al. BIOCONJUGATE CHEMISTRY
- Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
- (2016) Takashi Nakada et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Generating aldehyde-tagged antibodies with high titers and high formylglycine yields by supplementing culture media with copper(II)
- (2016) Dona York et al. BMC BIOTECHNOLOGY
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma
- (2016) Bishoy Faltas et al. Clinical Genitourinary Cancer
- New developments for antibody-drug conjugate-based therapeutic approaches
- (2016) Bart ECG de Goeij et al. CURRENT OPINION IN IMMUNOLOGY
- Development of BT1718, a Bicycle Drug Conjugate® (BDC) targeting MT1-MMP for treatment of solid tumours
- (2016) G. Bennett et al. EUROPEAN JOURNAL OF CANCER
- HER2-targeted antibody drug conjugates for ovarian cancer therapy
- (2016) Jing Jiang et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
- (2016) Alessandra Fabi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
- (2016) Aman P. Singh et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
- (2016) A. C. Phillips et al. MOLECULAR CANCER THERAPEUTICS
- A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity
- (2016) M. L. Miller et al. MOLECULAR CANCER THERAPEUTICS
- ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
- (2016) M. J. Flynn et al. MOLECULAR CANCER THERAPEUTICS
- Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates
- (2016) Patrick J. Burke et al. MOLECULAR CANCER THERAPEUTICS
- Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads
- (2016) Carolyn A. Leverett et al. ACS Medicinal Chemistry Letters
- Optimization of Tubulysin Antibody–Drug Conjugates: A Case Study in Addressing ADC Metabolism
- (2016) L. Nathan Tumey et al. ACS Medicinal Chemistry Letters
- Design and Synthesis of Tesirine, a Clinical Antibody–Drug Conjugate Pyrrolobenzodiazepine Dimer Payload
- (2016) Arnaud C. Tiberghien et al. ACS Medicinal Chemistry Letters
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- (2016) Kyoji Tsuchikama et al. Protein & Cell
- Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody–Drug Conjugates
- (2015) Remon van Geel et al. BIOCONJUGATE CHEMISTRY
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- The cryptophycins as potent payloads for antibody drug conjugates
- (2015) Vishal A. Verma et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics
- (2015) C. Peters et al. BIOSCIENCE REPORTS
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Influence of molecular size on tissue distribution of antibody fragments
- (2015) Zhe Li et al. mAbs
- IMGN853, a Folate Receptor- (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors
- (2015) O. Ab et al. MOLECULAR CANCER THERAPEUTICS
- HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors
- (2015) D. A. Proia et al. MOLECULAR CANCER THERAPEUTICS
- The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
- (2015) M. M. C. van der Lee et al. MOLECULAR CANCER THERAPEUTICS
- Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models
- (2015) F. Lhospice et al. MOLECULAR PHARMACEUTICS
- Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
- (2015) Ronald C. Elgersma et al. MOLECULAR PHARMACEUTICS
- Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
- (2015) Philipp Müller et al. Science Translational Medicine
- A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
- (2015) Laura R. Saunders et al. Science Translational Medicine
- Preparation of Well-Defined Antibody-Drug Conjugates through Glycan Remodeling and Strain-Promoted Azide-Alkyne Cycloadditions
- (2014) Xiuru Li et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates
- (2014) Patrick Dennler et al. BIOCONJUGATE CHEMISTRY
- Production of Site-Specific Antibody–Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System
- (2014) Erik S. Zimmerman et al. BIOCONJUGATE CHEMISTRY
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
- (2014) H. Uppal et al. CLINICAL CANCER RESEARCH
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications
- (2014) Andreas Maderna et al. JOURNAL OF MEDICINAL CHEMISTRY
- SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
- (2014) D. Sussman et al. MOLECULAR CANCER THERAPEUTICS
- Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
- (2014) S. Golfier et al. MOLECULAR CANCER THERAPEUTICS
- Improving the Therapeutic Index in Cancer Therapy by Using Antibody–Drug Conjugates Designed with a Moderately Cytotoxic Drug
- (2014) Serengulam V. Govindan et al. MOLECULAR PHARMACEUTICS
- Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
- (2014) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
- (2014) Amrita V. Kamath et al. PHARMACEUTICAL RESEARCH
- In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates
- (2014) Dowdy Jackson et al. PLoS One
- Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
- (2014) Parvin F. Peddi et al. Therapeutic Advances in Medical Oncology
- Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody–Drug Conjugation
- (2013) Nicole M. Okeley et al. BIOCONJUGATE CHEMISTRY
- A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology
- (2013) Scott C. Jeffrey et al. BIOCONJUGATE CHEMISTRY
- Hydrazino-Pictet-Spengler Ligation as a Biocompatible Method for the Generation of Stable Protein Conjugates
- (2013) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
- (2013) E. C. W. Breij et al. CANCER RESEARCH
- Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
- (2013) Pavel Strop et al. CHEMISTRY & BIOLOGY
- Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer
- (2013) Parvin F Peddi et al. Future Oncology
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Drug-conjugated antibodies for the treatment of cancer
- (2012) John M. Lambert BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format
- (2012) Kathrin Zuberbühler et al. CHEMICAL COMMUNICATIONS
- U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
- (2012) R. A. de Claro et al. CLINICAL CANCER RESEARCH
- Monoclonal antibody therapeutics: history and future
- (2012) Nicholas APS Buss et al. CURRENT OPINION IN PHARMACOLOGY
- The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
- (2012) H. K. Erickson et al. MOLECULAR CANCER THERAPEUTICS
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
- (2012) J. Y. Axup et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats
- (2011) C. Andrew Boswell et al. BIOCONJUGATE CHEMISTRY
- Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage
- (2011) Brenda A. Kellogg et al. BIOCONJUGATE CHEMISTRY
- Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
- (2011) Robert Y. Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and Biological Evaluation of Antibody Conjugates of Phosphate Prodrugs of Cytotoxic DNA Alkylators for the Targeted Treatment of Cancer
- (2011) Robert Yongxin Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
- (2010) Simone Jeger et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Gemtuzumab ozogamicin: is there room for salvage?
- (2010) W. T. Clarke et al. BLOOD
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
- (2009) Laurent Ducry et al. BIOCONJUGATE CHEMISTRY
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- (2009) H. Ikeda et al. CLINICAL CANCER RESEARCH
- Antibody-Drug Conjugate Targets
- (2009) B. Teicher CURRENT CANCER DRUG TARGETS
- Potent antibody drug conjugates for cancer therapy
- (2009) Peter D Senter CURRENT OPINION IN CHEMICAL BIOLOGY
- The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
- (2009) S. C. Alley et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Antibody-Drug Conjugates for Cancer Therapy
- (2008) Paul J. Carter et al. CANCER JOURNAL
- Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy
- (2008) Sung-Ju Moon et al. JOURNAL OF MEDICINAL CHEMISTRY
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started